FDA Gives Ozempic Two Drug Safety–Related Label Changes

The US Food and Drug Administration made two drug safety–related changes to the label for Ozempic, the weight-loss formulation of the GLP-1 receptor agonist semaglutide.
Medscape Medical News

source https://www.medscape.com/viewarticle/996912?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost